Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
Date | Price Target | Rating | Analyst |
---|---|---|---|
3/5/2024 | Buy | Berenberg | |
8/8/2023 | Equal-Weight | Morgan Stanley | |
11/16/2022 | Overweight → Equal-Weight | Morgan Stanley | |
1/11/2022 | Hold → Buy | Jefferies |
Berenberg initiated coverage of Zealand Pharma with a rating of Buy
Morgan Stanley resumed coverage of Zealand Pharma with a rating of Equal-Weight
Morgan Stanley downgraded Zealand Pharma from Overweight to Equal-Weight
Press release – No. 12 / 2025 Zealand Pharma to participate in upcoming investor conferences in September 2025 Copenhagen, Denmark, August 28, 2025 - Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that the company will participate in the following investor conferences in September 2025. Jefferies Swiss Healthcare Summit 2025, September 3 in Zürich Adam Lange, Vice President, Investor Relations, will host investor meetings on Wednesday, September 3. Cantor Global Healthcare Conference 2025, September 3-5 in New York Adam Steensberg, President and Chief Executive
Company announcement – No. 19 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Copenhagen, Denmark, August 20, 2025 – Zealand Pharma A/S ("Zealand") (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today reports receipt on 20 August 2025 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholder: As of 19 August 2025, Van Herk Investments B.V. (Dutch registration no. 59055057) holds nominally 7,115,191 shares (each share carrying one vote) in Zealand Pharma A/S, corresponding to 9.973% of the total share capital and 9.97
Company announcement – No. 18 / 2025 Zealand Pharma Announces Financial Results for the First Half of 2025Petrelintide collaboration with Roche off to a strong start, while key leadership appointments and solid financial position enable exciting next chapter for Zealand Pharma. Collaboration and license agreement with Roche to co-develop and co-commercialize petrelintide as a future foundational therapy for weight management off to a strong start, with further insight and updates expected at Roche's Pharma Day in September and Zealand Pharma's Capital Markets Day in December.Petrelintide program advancing at full speed, with ZUPREME Phase 2 trials progressing towards key milestones, and R
15F-12B - Zealand Pharma A/S (0001674988) (Filer)
S-8 POS - Zealand Pharma A/S (0001674988) (Filer)
S-8 POS - Zealand Pharma A/S (0001674988) (Filer)
SC 13G/A - Zealand Pharma A/S (0001674988) (Subject)
SC 13G/A - Zealand Pharma A/S (0001674988) (Subject)
Company announcement – No. 18 / 2025 Zealand Pharma Announces Financial Results for the First Half of 2025Petrelintide collaboration with Roche off to a strong start, while key leadership appointments and solid financial position enable exciting next chapter for Zealand Pharma. Collaboration and license agreement with Roche to co-develop and co-commercialize petrelintide as a future foundational therapy for weight management off to a strong start, with further insight and updates expected at Roche's Pharma Day in September and Zealand Pharma's Capital Markets Day in December.Petrelintide program advancing at full speed, with ZUPREME Phase 2 trials progressing towards key milestones, and R
Press Release – No. 11 / 2025 Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial results Copenhagen, Denmark, August 7, 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on August 14, 2025, at 2:00 pm CET (8:00 am ET) following the announcement of financial results for the second quarter of 2025. Participating in the call will be President and Chief Executive Officer, Adam Steensberg; Chief Financial Officer, Henriette Wennicke; Chief Medical Officer, David Kendall;
Company announcement – No. 14 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, June 6, 2025 – Zealand Pharma A/S ("Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, has by decision of the Board of Directors increased its share capital by a nominal amount of DKK 292,508 divided into 292,508 new shares with a nominal value of DKK 1 each. The capital increase is a consequence of the exercise of warrants granted under two of Zealand Pharma's employee warrant programs. Employee warrant programs are part of Zealand Pha
Press release – No. 9 / 2025 Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development Officer Steven will lead the regulatory and development strategies that position Zealand Pharma at the forefront of innovation in the management of obesity and other related complications He joins CMO David Kendall and recently appointed CSO Utpal Singh to strengthen Zealand Pharma's R&D leadership and progress its differentiated clinical pipeline of potential best-in-class peptide therapeutics Copenhagen, Denmark, May 19, 2025 – Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnolog
Press release – No. 5 / 2025 Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery Utpal joins Zealand Pharma at a pivotal moment as it aims to become a leader in the management of obesity and related complications He will lead the discovery and clinical translation of peptide medicines, investing in new technologies including data and computational science Utpal to expand the global scientific team to drive Zealand Pharma's next wave of highly differentiated, innovative therapies, building on the Company's strong drug development heritage Copenhagen, Denmark, 23 April 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL)
Company announcement – No. 40 / 2023 Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observers Copenhagen, Denmark, November 30, 2023 – a Zealand Pharma A/S (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced the appointment of pharmaceutical industry veterans Enrique Conterno and Elaine Sullivan as observers to the company's board of directors. It is expected that Enrique Conterno and Elaine Sullivan will stand for election to Zealand Pharma's board of directors at the company's 2024 Annual General Meeting. "As board observes, Enrique and Elaine collectively bring decades